Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin)

e21696 Background: Cancer-related anemia is an important factor that affects the clinical efficacy and quality of life for patients with advanced gastric cancer. This study is to observe the clinical efficacy of Yizhongshengxue Capsule, which is an herbal formula, on advanced gastric cancer-related anemia. Methods: A total of 96 eligible patients were randomized into three arms: 46 patients in the experimental arm, 26 patients in the positive control arm, and 24 patients in the negative control arm. All three arms received basic treatment of conventional medicine. Meanwhile, the experimental arm received Yizhongshengxue Capsule at the dosage of 3 capsules, 3 times daily. The positive control arm received Fufangejiao Syrup at the dosage of 20 ml, 3 times daily. The negative control arm received only basic treatment of western medicine. The course of treatment was 5 weeks. Results: After the 5-week-treatment, there was a statistically significant rise ( p<0.05) of hemoglobin(HGB) in both experimental arm and positive control arm. The negative control arm had no statistically difference of HGB ( p>0.05) before and after the treatment. Symptoms of dizziness, fatigue, loss of appetite, palpitation and insomnia in experimental arm were improved after the treatment ( p<0.05). Symptoms of fatigue and loss of appetite in positive control arm were alleviated after the treatment ( p<0.05). The negative control arm had no statistically difference in the above symptoms ( p>0.05) before and after the treatment. Furthermore, there was a significant improvement of dizziness, loss of appetite, palpitation and insomnia in the experimental arm compared to the negative control arm ( p<0.05). Finally, an improvement of the Karnofsky Performance Score(KPS) was seen only in the experimental arm after the treatment compared to that before the treatment ( p<0.05). Conclusions: Our study shows that Yizhongshengxue Capsule can not only improve the clinical symptoms and quality of life in patients with advanced gastric cancer-related anemia, but also reduce or even reverse the trend of HGB decrease. Therefore, it is very promising in treating cancer-related anemia. Clinical trial information: ChiCTR-TRC-13003604.

Download Full-text

Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD

Annals of Oncology ◽

10.1093/annonc/mdx262.015 ◽

2017 ◽

Vol 28 ◽

pp. iii142-iii143

Author(s):

Ian Chau ◽

Charles Fuchs ◽

Atsushi Ohtsu ◽

Astra Liepa ◽

Zhanglin Cui ◽

...

Keyword(s):

Quality Of Life ◽

Gastric Cancer ◽

Adverse Events ◽

Advanced Gastric Cancer ◽

Tumor Response

Download Full-text

Prospective multicentre randomised clinical trial comparing survival rates, quality of life and nutritional status between advanced gastric cancer patients with different follow-up intensities: study protocol for the STOFOLUP trial

BMJ Open ◽

10.1136/bmjopen-2021-056187 ◽

2021 ◽

Vol 11 (12) ◽

pp. e056187

Author(s):

Bang Wool Eom ◽

Dong-Hoe Koo ◽

Ji Yeong An ◽

Han Hong Lee ◽

Hyoung-Il Kim ◽

...

Keyword(s):

Quality Of Life ◽

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Cancer Patients ◽

Stomach Cancer ◽

Diagnostic Tools ◽

Life Questionnaire ◽

European Organization ◽

Free Survival

IntroductionPatients who underwent curative gastrectomy for gastric cancer are regularly followed-up for the early detection of recurrence and postoperative symptom management. However, there is a lack of evidence with regard to proper surveillance intervals and diagnostic tools. This study aims to evaluate whether frequent surveillance tests have a survival benefit or improve the quality of life in patients who underwent curative resection for advanced gastric cancer.Methods and analysisThe STOFOLUP trial is an investigator-initiated, parallel-assigned, multicentre randomised controlled trial involving 16 hospitals in the Republic of Korea. Patients (n=886) diagnosed with pathological stage II or III gastric adenocarcinoma will be randomised to either the 3-month or the 6-month group at a 1:1 ratio, stratified by trial site and tumour stage. Patients allocated to the 3-month group will undergo an abdominal CT scan every 3 months postoperatively and those allocated to the 6-month group will undergo CT every 6 months. The primary endpoint is 3-year overall survival and the secondary endpoints are quality of life, as assessed using KOrean QUality of life in Stomach cancer patients Study group-40, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the stomach cancer-specific module (STO22), and nutritional outcomes. Other survival data including data concerning 3-year disease-free survival, recurrence-free survival, gastric cancer-specific survival and postrecurrence survival will also be estimated. The first patient was enrolled on July 2021 and active patient enrolment is currently underway.Ethics and disseminationThis study has been approved by the Institutional Review Board of eight of the participating hospitals (NCC 2021-0085, KBSMC2021-01-059, SMC 2021-01-140, KC21OEDE0082, 4-2021-0281, AJIRB-MED-INT-20-608, 2021-0515 and H-2102-093-1198). This study will be disseminated through peer-reviewed publications, national or international conferences.Trial registration numberNCT04740346.

Download Full-text